Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Table 1

Indications addressed by gene therapy clinical trials up to January 2014.

Ranking	Indication	Number of trials ()	Percentage with respect to total gene therapy clinical trials (%)
1	Cancer diseases	1274	63.8
2	Monogenic diseases	178	8.9
3	Infectious diseases	164	8.2
4	Cardiovascular diseases	162	8.1
5	Healthy volunteers	52	2.6
6	Gene marking	50	2.5
7	Neurological diseases	37	1.9
8	Other diseases	35	1.8
9	Ocular diseases	31	1.6
10	Inflammatory diseases	13	0.7